Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd.
Read the full 328 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD